Date: 2016-06-24
Type of information: Termination of the agreement
Compound: AMG403 and AMG386 (trebananib)
Company: Takeda Pharmaceutical (Japan) Amgen (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: development licensing
Action mechanism:
Disease:
Details: * On June 24, 2016, Takeda Pharmaceutical announced revisions on an existing collaboration agreement, under which Takeda had rights to develop and commercialize multiple molecules / products from Amgen’s pipeline for the Japanese market. By the revisions, such rights for molecules / products including AMG403 and AMG386 will be returned to Amgen, effective immediately. Takeda and Amgen will continue to collaborate on the development and commercialization of remaining molecules / products for the Japanese market, including Vectibix® (panitumumab), a leading treatment for unresectable advanced or recurrent colorectal cancer. Takeda will work with Amgen to ensure a smooth transition of these molecules / products, and will cooperate with Amgen to ensure patients who receives study drug that include any of such molecules / products will receive appropriate therapies in Japan.
Financial terms:
Latest news:
